ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

larazotide acetate

Also written as “Larazotide Acetate”, “Larazotide” and “Larazotide acetate”.

Its studies are mostly in Celiac Disease · Fabry Disease, led by 3 companies.

Drug pageLarazotide acetate: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 14, 201812 company-led studies, 1 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
9 Meters Biopharmaits history only80 open or runningphase 3since Jun 14, 2018Aug 8, 2006none ahead
BioMarin Pharmaceuticalits history only30 open or runningphase 1since Nov 10, 2011Nov 10, 2011none ahead
Interlude Biopharmaits history only11 open or runningphase 3since Nov 10, 2026Nov 10, 2026Aug 2028phase 3 · NCT07944625

Also a collaborator on its studies: Teva Pharmaceutical Industries.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2006First study: phase 2 study in Celiac DiseaseNew to 9 Meters Biopharma9 Meters Biopharma · NCT00362856 · 80 enrolled · United States
  2. Oct 9, 20062 phase 1 studies in Celiac Disease9 Meters Biopharma · NCT00386490, NCT00386165
  3. Jun 25, 2007Phase 2 study in Celiac Disease9 Meters Biopharma · NCT00492960 · 171 enrolled · United States, Canada
  4. Feb 7, 2008Phase 2 study in Celiac Disease9 Meters Biopharma · NCT00620451 · 105 enrolled · United States, Canada, Spain
  5. Apr 27, 2009Phase 2 study in Celiac Disease9 Meters Biopharma · NCT00889473 · 42 enrolled · United States, Canada
  6. Jul 14, 2011Phase 2 study in Celiac Disease9 Meters Biopharma · NCT01396213 · 342 enrolled · United States, Canada
  7. Nov 10, 2011BioMarin Pharmaceutical’s first study: phase 1 study in Fabry DiseaseNew to BioMarin PharmaceuticalBioMarin Pharmaceutical · NCT01853852 · 14 enrolled · Australia
  8. Nov 8, 20122 phase 1 studies in Fabry DiseaseBioMarin Pharmaceutical · NCT01730482, NCT01730469
  9. Jun 14, 2018Phase 3 study in Celiac Disease9 Meters Biopharma · NCT03569007 · 307 enrolled · United States
  10. Nov 10, 2026Interlude Biopharma’s first study: phase 3 study in Celiac DiseaseNew to Interlude BiopharmaInterlude Biopharma · NCT07944625 · 414 planned

Ahead

  1. Aug 2028Primary completion: phase 3 study in Celiac DiseaseInterlude Biopharma · NCT07944625

TargetBeta

“Neuronal acetylcholine receptor; alpha3/beta4 partial agonist”ChEMBL 37, by rule

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07944625Celiac Disease3Not yet recruitingInterlude BiopharmaAug 2028414
NCT03569007Celiac Disease · United States3Terminated9 Meters BiopharmaJul 21, 2022307
NCT01730482Fabry Disease1CompletedBioMarin PharmaceuticalSep 20116
NCT01730469Fabry Disease · United States1CompletedBioMarin PharmaceuticalApr 201232
NCT01853852Fabry Disease · Australia1CompletedBioMarin PharmaceuticalDec 201114
NCT01396213Celiac Disease · United States, Canada2Completed9 Meters BiopharmaAug 20, 2013342
NCT00889473Celiac Disease · United States, Canada2Completed9 Meters BiopharmaNov 200942
NCT00620451Celiac Disease · United States, Canada, Spain2Completed9 Meters BiopharmaJul 2009105
NCT00492960Celiac Disease · United States, Canada2Completed9 Meters BiopharmaOct 2008171
NCT00386490Celiac Disease · United States1Completed9 Meters BiopharmaFeb 27, 200624
NCT00386165Celiac Disease · United States1Completed9 Meters BiopharmaJan 26, 200621
NCT00362856Celiac Disease · United States2Completed9 Meters BiopharmaMar 6, 200780

How it is read

Names in the registry

  • “larazotide acetate”, 5 entries
  • “Larazotide Acetate”, 2 entries
  • “Larazotide”, 1 entry
  • “Larazotide acetate”, 1 entry
  • “AT1001 150 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.